Novo Nordisk

Why Novo Nordisk should buy Uniqure
Why Novo Nordisk should buy Uniqure
EP Vantage
Novo Nordisk
gene editing
hemophilia
uniQure
Bluebird Bio
Flag link:
Novo taps bluebird bio for gene-editing tech
Novo taps bluebird bio for gene-editing tech
Fierce Biotech
Novo Nordisk
Bluebird Bio
R&D
gene editing
hemophilia
Flag link:
Novo Nordisk announces obesity digital health tie-up with Noom
Novo Nordisk announces obesity digital health tie-up with Noom
Pharmaforum
Novo Nordisk
Noom
digital health
obesity
Flag link:
Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019
Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019
Fierce Pharma
JNJ
Takeda
parents
Eli Lilly
Merck
Novo Nordisk
Sanofi
Flag link:
How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
Motley Fool
diabetes
Eli Lilly
Merck
Novo Nordisk
GSK
Byetta
Victoza
Bydureon
Ozempic
Tanzeum
Trulicity
Rybelsus
Flag link:
Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome
Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome
Pharmaforum
Novo Nordisk
oral semaglutide
Rybelsus
FDA
Flag link:
Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus
Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus
Fierce Pharma
Novo Nordisk
oral semaglutide
FDA
Rybelsus
type 2 diabetes
Flag link:
Novo and Sanofi make case for hypo-reducing insulins at EASD
Novo and Sanofi make case for hypo-reducing insulins at EASD
Pharmaforum
Novo Nordisk
Sanofi
EASD
diabetes
hypoglycemia
insulin
Lantus
Tresiba
Flag link:
How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal
How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal
Investors Business Daily
Novo Nordisk
Eli Lilly
oral semaglutide
Trulicity
diabetes
Flag link:
EASD: Novo's Ozempic tops Victoza, J&J's Invokana in double head-to-head win
EASD: Novo's Ozempic tops Victoza, J&J's Invokana in double head-to-head win
Fierce Pharma
Novo Nordisk
Ozempic
JNJ
Invokana
Victoza
diabetes
EASD
Flag link:
Factbox: Britain's insulin providers prepare for Brexit fallout
Factbox: Britain's insulin providers prepare for Brexit fallout
Yahoo/Reuters
Novo Nordisk
Eli Lilly
Sanofi
UK
Brexit
insulin
diabetes
Flag link:
Novo Nordisk and Medtronic to integrate diabetes technology
Novo Nordisk and Medtronic to integrate diabetes technology
Pharmaforum
Novo Nordisk
Medtronic
diabetes
devices
blood glucose monitoring
Flag link:
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
Yahoo/Benzinga
Merck
Pifeltro
FDA
Delstrigo
Novo Nordisk
oral semaglutide
Kodiak Sciences
MeiraGTx Holdings
IPOs
Exagen
IGM Biosciences
Arrowhead Pharmaceuticals
Lexicon Pharmaceuticals
Bluebird Bio
vTv Therapeutics
Flag link:
ICER dings Novo's new oral diabetes drug
ICER dings Novo's new oral diabetes drug
Biopharma Dive
Novo Nordisk
diabetes
ICER
oral semaglutide
Eli Lilly
Boehringer Ingelheim
Jardiance
Ozempic
Flag link:
Novo Nordisk to cut insulin prices for some U.S. diabetics
Novo Nordisk to cut insulin prices for some U.S. diabetics
Yahoo/Reuters
Novo Nordisk
drug pricing
Novolog
insulin
diabetes
Flag link:
Mark Your Calendar For These September PDUFA Dates
Mark Your Calendar For These September PDUFA Dates
Yahoo/Benzinga
FDA
Roche
Celgene
Tecentriq
Xeris Pharmaceuticals
Gvoke
Ardelyx
tenapanor
Merck
Pifeltro
Delstrigo
Novo Nordisk
semaglutide
JNJ
Genmab
daratumumab
Invokana
Flag link:
Novo Nordisk and Mylan Battle Over Generic Versions of Victoza
Novo Nordisk and Mylan Battle Over Generic Versions of Victoza
BioSpace
Novo Nordisk
Mylan
generics
Victoza
diabetes
Flag link:
Novo faces shareholder suit over insulin sales disclosures
Novo faces shareholder suit over insulin sales disclosures
Biopharma Dive
Novo Nordisk
insulin
investors
Flag link:
Novo Nordisk's new diabetes, obesity drugs lift sales outlook
Novo Nordisk's new diabetes, obesity drugs lift sales outlook
Yahoo/Reuters
Novo Nordisk
earnings
Flag link:
Novo extends R&D alliance with AI specialist e-Therapeutics
Novo extends R&D alliance with AI specialist e-Therapeutics
Pharmaforum
Novo Nordisk
R&D
e-therapeutics
artificial intelligence
Flag link:

Pages